Skip to main content
. Author manuscript; available in PMC: 2013 Jul 18.
Published in final edited form as: Calcif Tissue Int. 2013 Mar 21;93(1):1–14. doi: 10.1007/s00223-013-9724-8

Figure 4.

Figure 4

Maximum yearly cost (in €) for an adherence-enhancing intervention to be considered cost-effective. Data from [36, 37, 64].

For Sweden, improvement in medication adherence at 25% should be read at 30%. In Ireland, a longer refill gap period (9-weeks) was selected to define persistence resulting in higher base-case adherence levels.